---
layout: post
title: "Cassava Sciences(SAVA.US)盘前涨超8% FDA驳回申请暂停阿尔茨海默病药物试验的公民请愿书"
date: 2022-02-11 17:12:13 +0800
categories: zhitongcaijingwang
tags: 智通财经网新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/105.SAVA" data-code="SAVA|105|7" data-code2="SAVA|105|1|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=105.SAVA&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 SAVA_0" data-code="K SAVA|105|7" data-code2="K SAVA|105|1|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>2月11日(周五)美股盘前，截至发稿，Cassava Sciences(SAVA.US)涨8.01%，报57.3美元。消息面上，美国食品药物管理局(FDA)驳回了一份关于暂停Cassava Sciences阿尔茨海默病药物simufilam关键试验的公民请愿书。<br /></p><p class="em_media">（文章来源：智通财经网）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202202112274214883>

[返回智通财经网新闻](//finews.withounder.com/category/zhitongcaijingwang.html)｜[返回首页](//finews.withounder.com/)